These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32069381)

  • 1. From astrocytoma to glioblastoma: a clonal evolution study.
    Yang F; Zou Y; Gong Q; Chen J; Li WD; Huang Q
    FEBS Open Bio; 2020 May; 10(5):744-751. PubMed ID: 32069381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
    Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F
    J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
    Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW
    Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of p53 mutations during astrocytoma tumorigenesis.
    del Arco A; García J; Arribas C; Barrio R; Blázquez MG; Izquierdo JM; Izquierdo M
    Hum Mol Genet; 1993 Oct; 2(10):1687-90. PubMed ID: 8268922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 gene mutations and 17p deletions in human astrocytomas.
    Chung R; Whaley J; Kley N; Anderson K; Louis D; Menon A; Hettlich C; Freiman R; Hedley-Whyte ET; Martuza R
    Genes Chromosomes Cancer; 1991 Sep; 3(5):323-31. PubMed ID: 1686725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.
    van Meyel DJ; Ramsay DA; Casson AG; Keeney M; Chambers AF; Cairncross JG
    J Natl Cancer Inst; 1994 Jul; 86(13):1011-7. PubMed ID: 8007011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
    Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
    Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations associated with the evolution and progression of astrocytic brain tumours.
    Ohgaki H; Schäuble B; zur Hausen A; von Ammon K; Kleihues P
    Virchows Arch; 1995; 427(2):113-8. PubMed ID: 7582239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
    Fults D; Brockmeyer D; Tullous MW; Pedone CA; Cawthon RM
    Cancer Res; 1992 Feb; 52(3):674-9. PubMed ID: 1346255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
    Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
    Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.
    Smith JS; Tachibana I; Passe SM; Huntley BK; Borell TJ; Iturria N; O'Fallon JR; Schaefer PL; Scheithauer BW; James CD; Buckner JC; Jenkins RB
    J Natl Cancer Inst; 2001 Aug; 93(16):1246-56. PubMed ID: 11504770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal expansion of p53 mutant cells is associated with brain tumour progression.
    Sidransky D; Mikkelsen T; Schwechheimer K; Rosenblum ML; Cavanee W; Vogelstein B
    Nature; 1992 Feb; 355(6363):846-7. PubMed ID: 1311419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
    Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
    Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
    Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
    Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.